Jose Medina-Inojosa MD MSc

Assistant Professor of Epidemiology Mayo Clinic College of Medicine Researcher
Mayo Clinic Graduate School of Biomedical Sciences 2014-2016
Doctor of Medicine (M.D.), Medicine 2003-2010
Research
Cardiology
Healthcare
Preventive Medicine
Epidemiology
Pulmonary Disease

Register to MarketScale.com for Jose Medina-Inojosa episodes, events, and more.


Already have an account?

Recent Posts

Revolutionary Advancements in Hypertension Treatment: Zilebesiran Redefines the Landscape
Healthcare

Revolutionary Advancements in Hypertension Treatment: Zilebesiran Redefines the Landscape

Jose Medina-Inojosa - July 25, 2023

Assistant Professor of Epidemiology for the Mayo Clinic College of Medicine at Mayo Clinic, Jose Medina-Inojosa MD MSc, breaks down the groundbreaking innovation in hypertension treatment with the introduction of Zilebesiran. Published in the prestigious New England Journal of Medicine, this study has ignited excitement in the medical community, offering new hope for the millions affected by hypertension, the notorious "silent killer.

Read more
Revolutionary Advancements in Hypertension Treatment: Zilebesiran Redefines the Landscape
American Heart Association

Next Steps in Hypertension Management

Jose Medina-Inojosa - November 30, 2022

We tested the hypothesis that BF content measured by air displacement plethysmography (Bod-Pod®) had a stronger association with prevalent hypertension (HTN), diabetes mellitus (DM) and dyslipidemia (DLP) when compared to BMI.

Read more
Revolutionary Advancements in Hypertension Treatment: Zilebesiran Redefines the Landscape
American Heart Association

Association Between Arrhythmia Burden During Clinical Exercise Testing and All-Cause Mortality

Jose Medina-Inojosa - November 30, 2022

Arrhythmias commonly occur during clinical exercise stress testing (EST), however there are limited data on prognostic significance, particularly differences between individuals with minor versus significant arrhythmia burden. We hypothesized that significant but not minor arrhythmia burden during EST would be predictive of future all-cause mortality.

Read more
Cost Plus Drugs Mayo Clinic
Articles

Mayo Clinic Doctor Says Mark Cuban’s Cost Plus Drugs is Bringing “Access” to U.S. Healthcare

Jose Medina-Inojosa - November 11, 2022

Mark Cuban's Cost Plus Drugs is making waves in the pharmacy market, gaining more than 1.2 million customers and selling over 1000 generic low-cost drugs at a fraction of the prescription price that Big Pharma puts on the marketplace.

Read more
Cost Plus Drugs Mayo Clinic
American Heart Association

Innovative Insights Into Subclinical Cardiovascular Disease: coronary artery calcification and beyond

Jose Medina-Inojosa - October 30, 2022

We have previously shown that ECG-derived age (ECG-Age) predicts all-cause and cardiovascular (CV) mortality, reflecting physiologic age. We hypothesized that ECG-Age minus chronological age (Age-Gap) would be associated with coronary artery calcium (CAC) assessed by computer tomography.

Read more
Cost Plus Drugs Mayo Clinic
American Heart Association

A look into the future of exercise and cardiopulmonary fitness

Jose Medina-Inojosa - October 30, 2022

The physiological changes associated with aging have deleterious effects on cardiovascular function. In addition, increasing evidence showed the effect of exercise on improving cardiovascular health and reducing the aging process. The present study sought to demonstrate the association between exercise and biological age, estimated by our previously reported method using artificial intelligence-enabled electrocardiography (ECG).

Read more